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Background: Obstructive voiding symptoms (OVS) are common following prostate cancer treatment with radiation
therapy. The risk of urinary retention (UR) following hypofractionated radiotherapy has yet to be fully elucidated.
This study sought to evaluate OVS and UR requiring catheterization following SBRT for prostate cancer.
Methods: Patients treated with SBRT for localized prostate cancer from February 2008 to July 2011 at Georgetown
University were included in this study. Treatment was delivered using the CyberKnife® with doses of 35 Gy-36.25
Gy in 5 fractions. UR was prospectively scored using the CTCAE v.3. Patient-reported OVS were assessed using the
IPSS-obstructive subdomain at baseline and at 1, 3, 6, 9, 12, 18 and 24 months. Associated bother was evaluated
via the EPIC-26.
Results: 269 patients at a median age of 69 years received SBRT with a median follow-up of 3 years. The mean
prostate volume was 39 cc. Prior to treatment, 50.6% of patients reported moderate to severe lower urinary track
symptoms per the IPSS and 6.7% felt that weak urine stream and/or incomplete emptying were a moderate to big
problem. The 2-year actuarial incidence rates of acute and late UR ≥ grade 2 were 39.5% and 41.4%. Alpha-antagonist
utilization rose at one month (58%) and 18 months (48%) post-treatment. However, Grade 3 UR was low with only 4
men (1.5%) requiring catheterization and/or TURP. A mean baseline IPSS-obstructive score of 3.6 significantly increased
to 5.0 at 1 month (p < 0.0001); however, it returned to baseline in 92.6% within a median time of 3 months. Late
increases in OVS were common, but transient. Only 7.1% of patients felt that weak urine stream and/or incomplete
emptying was a moderate to big problem at two years post-SBRT (p = 0.6854).
Conclusions: SBRT treatment caused an acute increase in OVS which peaked within the first month post-treatment,
though acute UR requiring catheterization was rare. OVS returned to baseline in > 90% of patients within a median
time of three months. Transient Late increases in OVS were common. However, less than 10% of patients felt that OVS
were a moderate to big problem at two years post-SBRT.
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Benign prostatic hyperplasia (BPH) and related lower
urinary tract symptoms (LUTS) are a common problem
of male aging [1]. LUTS consists of both irritative and
obstructive voiding symptoms [1,2]. In men greater than
seventy years old, the prevalence of LUTS may be as
high as 30% [3]. Older age [4], non-Caucasian race [5],
comorbidities [6], and obesity [5] may increase the risk
of LUTS.
Obstructive voiding symptoms commonly occur fol-
lowing external beam radiation therapy (EBRT) for pros-
tate cancer and may adversely affect a patient’s quality of
life [7,8]. The cause of these symptoms may involve
prostatic edema, however the etiology is not fully under-
stood [9-11]. Patients report incomplete emptying, inter-
mittency, weak stream and straining [2], which develop
days to weeks after the start of treatment and generally
resolve weeks to months following completion of EBRT
[12-15]. Patient characteristics including prostatic vol-
ume [14,16,17], IPSS score [11,17-19], BPH [20], and
prior procedures for BPH [19,21] may contribute to an in-
dividual’s risk of radiation-induced UR [22]. Pre-treatment
androgen deprivation therapy (ADT) [23,24] and/or post-
treatment alpha agonists [25,26] may decrease treatment-
related symptoms.
Brachytherapy is an effective and convenient treatment
option for clinically localized prostate cancer [27-30].
Obstructive voiding symptoms are the primary urinary
morbidity following brachytherapy. Treatment-related
factors such as physician experience [31,32], isotope se-
lection [33,34] and/or the number of needle applicators
utilized [35,36] may affect the incidence and severity of
obstructive voiding symptoms. Acute urinary retention
(AUR) is common and may occur in 5-20% of patients
[31]. In some cases, prolonged catheterization and/or
transurethral resection of the prostate (TURP) are re-
quired, which increase the risk of long term urinary incon-
tinence [37]. Intraoperative image-optimized delivery may
reduce, but not eliminate, urinary toxicity [38,39]. The
negative impact of AUR on quality of life (QoL) is
high and lasts for years after the catheter has been
removed [40].
Stereotactic Body Radiation Therapy (SBRT) is a safe
and effective treatment for clinically localized prostate
cancer [41-45]. The larger dose per fraction untilized
in SBRT offers the potential radiobiological benefits of
hypofractionation [46]. Initial reports suggest that the
incidence of urinary obstruction following SBRT is
comparable to other external radiotherapy modalities,
and may be less than brachytherapy [41-43]. The goal
of this study is to report the incidence and prevalence
of obstructive voiding symptoms and urinary reten-
tion following SBRT for clinically localized prostate
cancer.Methods
Patient selection
Georgetown University Hospital established its Prostate
SBRT Program in 2006. As of December 2013, 700 pros-
tate cancer patients have been treated with SBRT plus
or minus supplemental external beam radiation therapy.
At the inception of our program, a prospective database
was established to record baseline patient characteristics.
At each follow-up visit, toxicity and quality of life data
have also been prospectively collected and recorded. Pa-
tients eligible for this study were those who had SBRT
monotherapy for clinically localized prostate cancer and
a minimum of two years of follow-up. Internal Review
Board (IRB) approval was obtained for retrospective
review of our database.
SBRT treatment planning and delivery
SBRT treatment planning and delivery were conducted
as previously described [47,48]. Briefly, four to six stranded
gold fiducials (1013- 2-2, Best Medical International, Inc.,
Springfield, VA, USA) were placed into the prostate with
two to three needle applicators via a trans-rectal or trans-
perineal approach. Fused computed tomography (CT) and
magnetic resonance magnetic resonance (MR) images were
used for treatment planning. The clinical target volume
(CTV) included the prostate and the proximal seminal ves-
icles. The planning target volume (PTV) equaled the CTV
expanded 3 mm posteriorly and 5 mm in all other dimen-
sions. The prescription dose was 35-36.25 Gy to the PTV
delivered in five fractions of 7-7.25 Gy over one to two
weeks. The prescription isodose line was limited to ≥ 75%,
which limited the maximum prostatic urethra dose to
133% of the prescription dose. The membranous urethra
was contoured and evaluated with dose-volume histogram
analysis during treatment planning using Multiplan
(Accuray Inc., Sunnyvale, CA). The dose-volume histo-
gram (DVH) goal was for < 50% membranous urethra to
receive 37 Gy. To minimize the risk of local recurrence,
the dose to the prostatic urethra was not constrained [49].
Prostate position was verified during treatment using
paired, orthogonal x-ray images [50].
Follow-up and statistical analysis
Toxicity and quality of life data were obtained before
treatment and during routine follow-up visits every
3 months for the first year and every six months for
the second year. Alpha-antagonist utilization was docu-
mented at each visit. Physician-reported toxicity was
prospectively documented at follow-up visits using the
National Cancer Institute (NCI) Common Toxicity Cri-
teria (CTC) version 3.0. Toxicity that occurred between
assessments was assigned to the later time point. For
example, if a toxicity occurred one week after SBRT it
was recorded at one month post-SBRT. Acute toxicity
Table 1 Baseline patient characteristics and treatment
% Patients
(N = 269)









Baseline PSA (ng/dL) Median 6.2 (0.2-32.5)
Prostate Volume (cc) Median 39.04 (11.56-138.69)
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of SBRT and late toxicity was defined as occurring
greater than 6 months after delivery of SBRT. Grade 1
urinary retention consisted of dribbling or hesitancy
not requiring medications for symptom control. Grade
2 urinary retention indicates hesitancy requiring new
medication (i.e. alpha-antagonist) or increase in dose
of previously prescribed medication. Urinary retention
requiring catheterization and/or transurethral resection of
the prostate was scored as Grade 3.
Patient-reported obstructive voiding symptoms were
assessed via the International Prostate Symptom Score
(IPSS), a validated questionnaire where higher scores
indicate more severe symptoms [2]. The recall period for
the IPSS is one month [51]. The IPSS includes four
question related to obstructive symptoms (incomplete
emptying, intermittency, weak stream and straining). For
each IPSS obstructive question, the responses were grouped
into four clinically relevant categories (never, < ½ time, ≥ ½
time and always). The IPSS obstructive subscore (IPSS-O)
has been previously defined as the sum of the scores for
questions 1, 3, 5, and 6 [52]. Overall IPSS-O scores ranged
from 0 - 20. IPSS-0 resolution was defined as a return to
within one point of the baseline score [13]. Bother with
obstructive urinary symptoms was assessed via Question
4d of the Expanded Prostate Index Composite (EPIC)-26
(“How big a problem, if any, has weak urine stream or
incomplete emptying been for you during the last four
weeks?”) [53] for which responses were grouped into three
clinically relevant categories (no problem, small problem
and moderate to big problem).
Student’s t-test and Wilcoxon signed-rank test were
used to assess differences in ongoing toxicity and quality
of life scores in comparison to baseline. Sample medians
and ranges were used to describe continuous variables.
Actuarial likelihood estimates for late urinary retention ≥
grade 2 and time to IPSS-O resolution were determined
using the Kaplan-Meier method. To statistically compare
changes between time points, the levels of responses
were assigned a score and the significance of the mean
changes in the scores was assessed by paired t test. The
minimally important difference (MID) in IPSS-O score
was defined as a change of one-half standard deviation
(SD) from the baseline [54]. To limit the effect of attri-
tion bias, statistical analysis was limited to time points
in which ≥ 80% of the patient data were available.
Results
From February 2008 to July 2011, 269 prostate cancer
patients were treated per our institutional SBRT mono-
therapy protocol (Table 1) with a median follow-up of
3 years. They were ethnically diverse with a median age
of 69 years (range, 44-90 years). The median prostate
volume was 39 cc and 10% had prior procedures forBPH including simple prostatectomy (1 patient), TURP
(10 patients), TUNA (1 patient) and TUMT (7 patients).
The median baseline IPSS was 8, and 32% of patients
were using alpha-antagonists prior to SBRT. One patient
utilized intermittent catheterization prior to treatment.
By D’Amico classification, 99 patients were low-, 143
intermediate-, and 27 high-risk. Sixteen percent of pa-
tients received androgen deprivation therapy (ADT) via
a gonadotropin-releasing hormone agonist for a median
duration of 3 months (range, 3-24 months). Eighty three
percent of patients were treated with 36.25 Gy in five
7.25 Gy fractions.
Table 2 Prevalence of CTC graded urinary retention at each follow-up
1 Mon 3 Mon 6 Mon 9 Mon 12 Mon 18 Mon 24 Mon
Grade 0 41.7% 57.7% 55.0% 58.7% 56.2% 54.5% 55.4%
Grade 1 21.6% 16.6% 20.7% 19.0% 18.7% 19.3% 21.2%
Grade 2 36.7% 25.7% 23.9% 21.9% 25.1% 25.8% 23.0%
Grade 3 0.0% 0.0% 0.4% 0.4% 0.0% 0.4% 0.5%
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ment is shown in Table 2. The corresponding 2-year
actuarial incidence of acute and late UR ≥ grade 2 was
39.5% and 41.4%, respectively (Figure 1A). Alpha-
antagonist use rose at one month (57.9%) and 18 months
(48.0%) post-treatment (Figure 1B). However, Grade 3 UR
was low with only 4 men (1.5%) requiring catheterization
and/or TURP.
The majority of patients had obstructive voiding symp-
toms prior to treatment with a mean baseline IPSS-O
score of 3.7 (Table 3, Figure 2A). At one month post-
SBRT, the mean IPSS-O significantly increased to 5.0
(p < 0.0001), but returned to baseline at 3 months (p = 0.74,
Figure 2A). This increase was of borderline clinical
significance (MID = 1.8). The median time to IPSS-O
normalization was 3 months (Figure 2B). The IPSS-O
returned to baseline in 79.6% of patients by 6 months
and 92.6% by 2 years (Figure 2B). Late IPSS-O in-
creases were common, but transient (Figure 2A). Indi-
vidual obstructive voiding symptoms (incomplete
emptying, intermittency, weak stream and straining)
followed a similar trend (Table 4).
At baseline, 44.9% of our cohort reported some level
of bother due to weak stream and/or incomplete empty-
ing with 6.7% of patients feeling it was a moderate to big
problem (Table 5, Figure 3). At one month post-SBRT,
moderate to big bother with obstructive voiding symp-
toms increased to 10.4% (p < 0.0001), but reduced toFigure 1 Acute and late grade 2 urinary retention. (A) Cumulative
retention ≥ grade 2. (B) Proportion of patients utilizing α1A antagonists5.1% at 3 months (p = 0.79). Although bother declined
quickly, a second late transient increase in bother oc-
curred at one year (Table 5, Figure 3). However, only
7.1% of patients felt that weak urine stream and/or
incomplete emptying was a moderate to big problem at
two years post-SBRT (p = 0.6854).
Discussion
Obstructive voiding symptoms following prostate cancer
radiotherapy are common and an important quality of
life issue [7]. A better understanding of the pattern of
obstructive voiding symptoms following SBRT will en-
able clinicians to provide more realistic expectations to
patients [55]. In this study, we utilized validated QoL
questionnaires to comprehensively evaluate obstructive
voiding symptoms following SBRT [2,53].
An increase in obstructive voiding symptoms is a
common response to prostate radiotherapy. This study
shows that SBRT acutely increases all obstructive voiding
symptoms (incomplete emptying, intermittency, weak
stream and straining) in a similar manner. The 2-year
actuarial incidence rates of acute and late UR ≥ grade 2
in this series were 39.5% and 41.4%, respectively. New
alpha-antagonist use or alpha-antagonist dose increase
were the most common indications of grade 2 toxicities.
It is our institutional policy to proscribe alpha-antagonists
for mild to moderate LUTS, and this may explain the high
rate of GU toxicity ≥ grade 2 seen in this study [47].acute (≤6 months post-RT) and late (>6 months post-RT) urinary
at each time point.
Table 3 Changes in IPSS-O scores following SBRT for prostate cancer
Baseline 1 Month 3 Month 6 Month 9 Month 12 Month 18 Month 24 Month
S.D. Change S.D. Change S.D. Change S.D. Change S.D. Change S.D. Change S.D. Change S.D.
IPSS Obstructive 3.7 3.61 1.3 3.91 −0.2 3.31 −0.6 3.13 0.2 4.06 0.4 0.25 −0.2 3.69 −0.3 3.70
S.D., standard deviation.
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for IMRT [56] and brachytherapy [31]. To maximize pa-
tient comfort, it is currently our institutional policy to ini-
tiate prophylactic alpha antagonist use [57] and to treat on
an every other day schedule [58].
Post-SBRT urinary symptoms may be exacerbated by
high radiation doses to the center of the prostate [47].
With the aim of reducing urinary symptoms, we have
modified our institutional protocol. Specifically, we have
reduced the anterior/superior PTV expansion to reduce
the bladder neck dose. In addition, it is now our practice
to prescribe to ≥ 80% isodose line to reduce the central
hot spot that may involve the prostatic urethra. We be-
lieve that such modifications will reduce the incidence
and severity of urinary symptoms.
Due to its effectiveness and convenience, brachyther-
apy is a common treatment option for prostate cancer.
Post-implant UR is a common (5-20%) toxicity that may
impact long-term quality of life. Risk factors for post-
implant UR include large prostate volume, high pretreat-
ment IPSS score and BPH. Our patients were old with
poor baseline urinary function, yet the incidence of UR
following SBRT in this series was low (<5%). This low
incidence was possibly due to limited needle trauma
and/or the use of neoadjuvant ADT in patients with
large prostate volumes and high pretreatment IPSS
scores [24]. Because of the limited number of events,
this study could not determine risk factors for UR fol-
lowing SBRT. If cancer control is similar, SBRT may be aFigure 2 Obstructive voiding symptoms following SBRT for prostate c
in average scores over time. IPSS-O scores range from 0–20 with higher value
for clinically significant changes in scores (½ standard deviation above and be
confidence intervals. (B) Time to IPSS-O resolution (return to within one pointconvenient treatment option for patients at high risk of
UR following brachytherapy [14,19].
IPSS resolution following brachytherapy varies from
months to years [13,15,31]. As seen in other SBRT series
[41], our mean IPSS scores returned to baseline within
three months post-SBRT. A minority of patients experi-
enced a transient increase in obstructive voiding symp-
toms greater than six months after the completion of
SBRT. As with brachytherapy, late urinary symptom
flare [59-61] occurred in a minority of our patients and
resolved with conservative management. Knowledge of
this late increase in obstructive voiding symptoms and
their resolution with conservative management will en-
able clinicians to address patient concerns and prevent
unnecessary catheterization and/or TURP.
Bother is defined as the degree of interference or an-
noyance caused by a symptom [15,62]. Similar to other
radiation modalities, bother with weak stream and/or
incomplete voiding plateaued within the first month fol-
lowing treatment with 10% of men reporting a moderate
to big problem. This change compares favorably to that
reported at two months with conventionally fractionated
external beam radiation therapy (23%) and brachyther-
apy (40%) [7]. As see with external beam radiation ther-
apy, this increase in bother was transient and returned
to baseline by 3 months post-SBRT. A second increase
in bother occurred 12 months post-SBRT with 11% of
patients reporting moderate to big bother at this time
point. This change is comparable to that reported atancer. (A) Mean IPSS-O score. The graphs show unadjusted changes
s representing worsening obstructive voiding symptoms. The thresholds
low the baseline) are marked with dashed lines. Error bars indicate 95%
of the baseline score).
Table 4 Obstructive voiding symptoms following SBRT for prostate cancer: patient-reported responses to IPSS questions 1
(incomplete emptying), 3 (intermittency), 5 (weak stream) and 6 (straining)
Start 1 Mon 3 Mon 6 Mon 9 Mon 12 Mon 18 Mon 24 Mon
Incomplete Voiding
Never 45.1% 26.8% 36.6% 45.6% 40.4% 37.8% 42.9% 44.1%
< 1/2 times 42.2% 52.5% 53.7% 47.2% 45.2% 46.7% 46.0% 43.3%
< 1/2 times 11.2% 18.0% 7.4% 6.8% 12.0% 14.6% 8.8% 8.8%
Always 2.6% 2.7% 2.7% 1.2% 3.2% 1.6% 3.1% 4.2%
p <0.0001 0.747 0.1302 0.5017 0.2546 0.5802 0.7787
Intermittency
Never 45.9% 33.3% 45.1% 50.0% 45.2% 43.5% 51.3% 50.8%
< 1/2 times 40.3% 51.0% 47.5% 42.4% 43.6% 39.4% 37.2% 39.1%
< 1/2 times 12.3% 13.4% 5.1% 6.8% 9.2% 15.4% 9.7% 9.2%
Always 1.5% 2.3% 2.3% 0.8% 2.0% 1.6% 1.8% 0.8%
p 0.0025 0.1411 0.0156 0.7464 0.8765 0.1081 0.0225
Weak Stream
Never 42.7% 26.8% 37.7% 42.8% 37.2% 34.1% 41.2% 40.3%
< 1/2 times 40.8% 46.7% 48.6% 42.0% 43.2% 48.0% 41.6% 45.4%
< 1/2 times 11.2% 22.6% 10.9% 13.2% 16.8% 13.4% 12.8% 10.9%
Always 5.2% 3.8% 2.7% 2.0% 2.8% 4.5% 4.4% 3.4%
p <0.0001 0.9055 0.6035 0.1365 0.1183 0.7275 0.6782
Straining
Never 72.4% 60.2% 74.3% 73.9% 68.4% 65.0% 72.4% 75.6%
< 1/2 times 24.6% 33.3% 22.6% 23.7% 25.6% 29.3% 24.4% 20.6%
< 1/2 times 1.9% 5.7% 2.7% 2.4% 4.8% 5.3% 3.1% 3.4%
Always 1.1% 0.8% 0.4% 0.0% 1.2% 0.4% 0.4% 0.4%
p 0.0001 0.7224 0.2286 0.1191 0.0482 0.7608 0.3241
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(15%) [8], proton therapy (11%) [8] and brachytherapy
(18%) [7]. Unlike brachytherapy, though, bother follow-
ing SBRT returned to near baseline by two years.
Our study has several limitations. There was a poor cor-
relation between physician-reported toxicity and patient-
reported outcomes. The prescription of an alpha-antagonist
for obstructive urinary symptoms was not guided by a
standard protocol [12]. It is possible, that many patientsTable 5 Bother from weak urine stream and/or incomplete emp
responses to question 4d of the EPIC-26)
Start 1 Mon 3 Mon
No Problem 55.1% 38.2% 53.9%
Very small-small problem 38.2% 51.4% 41.0%
Moderate-big problem 6.7% 10.4% 5.1%
N= 267 259 256
p <0.0001 0.795994with mild obstructive urinary symptoms received alpha-
antagonists and were inappropriately scored a Grade 2
toxicity. Alternatively, the high rate of alpha-antagonist
utilization in this study may have hidden the true inci-
dence of patient reported obstructive voiding symptoms
with SBRT. In addition, most late obstructive voiding
symptoms were transient and associated bother may
have been missed due to the timing of questionnaire
administration [51].tying following SBRT for prostate cancer (patient-reported
6 Mon 9 Mon 12 Mon 18 Mon 24 Mon
53.2% 52.6% 49.0% 55.1% 55.6%
42.8% 39.4% 39.6% 38.2% 37.2%
4.0% 8.0% 11.4% 6.7% 7.1%
250 249 245 225 239
0.841946 0.197648 0.021191 1 0.68536
Figure 3 Bother with weak stream and/or incomplete emptying at baseline and following SBRT for prostate cancer, question 4d of
the EPIC-26. Patients were stratified to three groups: no problem, very small to small problem and moderate to big problem. The percentage
of patients in each group at each time point is depicted in the bar chart.
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SBRT is a convenient treatment option for patients with
clinically localized prostate cancer. Treatment resulted
in an acute increase in obstructive urinary symptoms
which peaked within the first month post-SBRT. These
symptoms returned to baseline in the majority of pa-
tients by 6 months and in > 90% by 2 years. The risk of
acute urinary retention requiring catheterization was
low, and late increases in obstructive voiding symptoms
were common, though transient. Overall, bother with
obstructive voiding symptoms was at baseline two years
post SBRT.
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